Funding round brings in $75M for Ultragenyx

12/21/2012 | North Bay Business Journal (Santa Rosa, Calif.)

Ultragenyx Pharmaceutical secured $75 million in a Series B funding round and will use the money to further develop its lead drug candidates, UX001 and UX003. UX001 is being developed as a replacement therapy for hereditary inclusion body myopathy, while UX003 is an experimental enzyme replacement therapy for mucopolysaccharidosis type 7.

View Full Article in:

North Bay Business Journal (Santa Rosa, Calif.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
White Plains, NY
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ